 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug DOXEPIN HCL: The FDAHandler has indicated that the FDA label for DOXEPIN HCL does not contain information regarding the effect of DOXEPIN HCL on the risk of mortality after [0m
[34mmyocardial infarction. Therefore, based on the available FDA label data, I cannot determine whether DOXEPIN HCL increases or decreases the risk of mortality after myocardial infarction.[0m

[34m DO-NOT-KNOW[0m

[34mThe justification for this answer is that the FDA label for DOXEPIN HCL, as provided by the FDAHandler, does not mention any information about the drug's impact on mortality post-myocardial [0m
[34minfarction. Without this specific information in the FDA label, it is not possible to ascertain the effect of DOXEPIN HCL on mortality risk after a myocardial infarction.[0m
[1;34m2[0m[34m. Drug DESIPRAMINE: DO-NOT-KNOW[0m

[34mThe information provided by FDAHandler from the DESIPRAMINE label did not specifically mention the risk of mortality after myocardial infarction. Therefore, based on the FDA label data, it is not [0m
[34mpossible to determine whether DESIPRAMINE increases or decreases the risk of mortality after myocardial infarction.[0m
[1;34m3[0m[34m. Drug AMITRIPTYLINE HCL: AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction if used inappropriately or in overdose situations. This is based on the information provided[0m
[34mby FDAHandler, which indicates that AMITRIPTYLINE HCL is not recommended for use during the acute recovery phase following myocardial infarction due to the potential for increased QT interval and [0m
[34mincreased risk for arrhythmia. Overdosage of tricyclic antidepressants like Amitriptyline HCL can lead to severe cardiovascular complications, including cardiac dysrhythmias and severe hypotension, [0m
[34mwhich can be fatal.[0m
[34m                ---------[0m
[34m                Does the tricyclic antidepressant category of drugs increase the risk of[0m
[34m                mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the tricyclic antidepressant category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that there is no information available in the FDA label for DOXEPIN HCL regarding its effect on mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Passage 2 also indicates a lack of information in the FDA label for DESIPRAMINE regarding its effect on mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Passage 3 suggests that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction, especially if used inappropriately or in overdose situations, due to the potential for [0m
[32mincreased QT interval and risk for arrhythmia."[0m[32m,[0m
[32m      [0m[32m"Based on the available information, there is evidence that at least one drug in the tricyclic antidepressant category [0m[32m([0m[32mAMITRIPTYLINE HCL[0m[32m)[0m[32m can increase the risk of mortality post-myocardial [0m
[32minfarction, while for the other drugs [0m[32m([0m[32mDOXEPIN HCL and DESIPRAMINE[0m[32m)[0m[32m, the effect is unknown due to lack of specific information."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The tricyclic antidepressant category of drugs may increase the risk of mortality after myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the tricyclic antidepressant category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that there is no information available in the FDA label for DOXEPIN HCL regarding its effect on mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Passage 2 also indicates a lack of information in the FDA label for DESIPRAMINE regarding its effect on mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Passage 3 suggests that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction, especially if used inappropriately or in overdose situations, due to the potential for [0m
[34mincreased QT interval and risk for arrhythmia."[0m[34m,[0m
[34m      [0m[34m"Based on the available information, there is evidence that at least one drug in the tricyclic antidepressant category [0m[34m([0m[34mAMITRIPTYLINE HCL[0m[34m)[0m[34m can increase the risk of mortality post-myocardial [0m
[34minfarction, while for the other drugs [0m[34m([0m[34mDOXEPIN HCL and DESIPRAMINE[0m[34m)[0m[34m, the effect is unknown due to lack of specific information."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The tricyclic antidepressant category of drugs may increase the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the tricyclic antidepressant category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that there is no information available in the FDA label for DOXEPIN HCL regarding its effect on mortality after myocardial infarction.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m also indicates a lack of information in the FDA label for DESIPRAMINE regarding its effect on mortality after myocardial infarction.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m suggests that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction, especially if used inappropriately or in overdose situations, due to the potential for [0m
[31mincreased QT interval and risk for arrhythmia.[0m
[1;31m4[0m[31m. Based on the available information, there is evidence that at least one drug in the tricyclic antidepressant category [0m[1;31m([0m[31mAMITRIPTYLINE HCL[0m[1;31m)[0m[31m can increase the risk of mortality post-myocardial [0m
[31minfarction, while for the other drugs [0m[1;31m([0m[31mDOXEPIN HCL and DESIPRAMINE[0m[1;31m)[0m[31m, the effect is unknown due to lack of specific information.[0m
[31m        -----[0m
[31m        Final answer: The tricyclic antidepressant category of drugs may increase the risk of mortality after myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is generally correct. The user has correctly identified that there is no information available for DOXEPIN HCL and DESIPRAMINE regarding their effect on [0m
[32mmortality after myocardial infarction, and that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction. The conclusion that the tricyclic antidepressant category of drugs may[0m
[32mincrease the risk of mortality after myocardial infarction is based on the evidence provided for AMITRIPTYLINE HCL. However, it is important to note that the reasoning should also consider the overall[0m
[32mevidence for the entire drug category. If the majority of drugs within the category do not have evidence suggesting an increased risk, and only one drug has such evidence, the conclusion should be [0m
[32mmore cautiously stated. The degree of certainty and the magnitude of change in risk should be clearly expressed, considering that the evidence is not uniform across the category."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is generally correct. The user has correctly identified that there is no information available for DOXEPIN HCL and DESIPRAMINE regarding their effect on [0m
[34mmortality after myocardial infarction, and that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction. The conclusion that the tricyclic antidepressant category of drugs may[0m
[34mincrease the risk of mortality after myocardial infarction is based on the evidence provided for AMITRIPTYLINE HCL. However, it is important to note that the reasoning should also consider the overall[0m
[34mevidence for the entire drug category. If the majority of drugs within the category do not have evidence suggesting an increased risk, and only one drug has such evidence, the conclusion should be [0m
[34mmore cautiously stated. The degree of certainty and the magnitude of change in risk should be clearly expressed, considering that the evidence is not uniform across the category."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is generally correct. The user has correctly identified that there is no information available for DOXEPIN HCL and DESIPRAMINE regarding their effect on [0m
[31mmortality after myocardial infarction, and that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction. The conclusion that the tricyclic antidepressant category of drugs may[0m
[31mincrease the risk of mortality after myocardial infarction is based on the evidence provided for AMITRIPTYLINE HCL. However, it is important to note that the reasoning should also consider the overall[0m
[31mevidence for the entire drug category. If the majority of drugs within the category do not have evidence suggesting an increased risk, and only one drug has such evidence, the conclusion should be [0m
[31mmore cautiously stated. The degree of certainty and the magnitude of change in risk should be clearly expressed, considering that the evidence is not uniform across the category.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the tricyclic antidepressant category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that there is no information available in the FDA label for DOXEPIN HCL regarding its effect on mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Passage 2 also indicates a lack of information in the FDA label for DESIPRAMINE regarding its effect on mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"Passage 3 suggests that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction, especially if used inappropriately or in overdose situations, due to the potential for [0m
[32mincreased QT interval and risk for arrhythmia."[0m[32m,[0m
[32m      [0m[32m"Given that two out of three drugs in the tricyclic antidepressant category have no clear evidence regarding their effect on mortality post-myocardial infarction, and only one drug has evidence [0m
[32msuggesting an increased risk, it is not possible to make a definitive conclusion about the entire category based on the available information."[0m[32m,[0m
[32m      [0m[32m"The evidence for an increased risk is specific to AMITRIPTYLINE HCL and may not be generalizable to the entire category of tricyclic antidepressants."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear overall effect of the tricyclic antidepressant category of drugs on the risk of mortality after myocardial infarction, as the evidence is not uniform across the [0m
[32mcategory."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the tricyclic antidepressant category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that there is no information available in the FDA label for DOXEPIN HCL regarding its effect on mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Passage 2 also indicates a lack of information in the FDA label for DESIPRAMINE regarding its effect on mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"Passage 3 suggests that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction, especially if used inappropriately or in overdose situations, due to the potential for [0m
[34mincreased QT interval and risk for arrhythmia."[0m[34m,[0m
[34m      [0m[34m"Given that two out of three drugs in the tricyclic antidepressant category have no clear evidence regarding their effect on mortality post-myocardial infarction, and only one drug has evidence [0m
[34msuggesting an increased risk, it is not possible to make a definitive conclusion about the entire category based on the available information."[0m[34m,[0m
[34m      [0m[34m"The evidence for an increased risk is specific to AMITRIPTYLINE HCL and may not be generalizable to the entire category of tricyclic antidepressants."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear overall effect of the tricyclic antidepressant category of drugs on the risk of mortality after myocardial infarction, as the evidence is not uniform across the [0m
[34mcategory."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the tricyclic antidepressant category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that there is no information available in the FDA label for DOXEPIN HCL regarding its effect on mortality after myocardial infarction.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m also indicates a lack of information in the FDA label for DESIPRAMINE regarding its effect on mortality after myocardial infarction.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m suggests that AMITRIPTYLINE HCL may increase the risk of mortality after myocardial infarction, especially if used inappropriately or in overdose situations, due to the potential for [0m
[31mincreased QT interval and risk for arrhythmia.[0m
[1;31m4[0m[31m. Given that two out of three drugs in the tricyclic antidepressant category have no clear evidence regarding their effect on mortality post-myocardial infarction, and only one drug has evidence [0m
[31msuggesting an increased risk, it is not possible to make a definitive conclusion about the entire category based on the available information.[0m
[1;31m5[0m[31m. The evidence for an increased risk is specific to AMITRIPTYLINE HCL and may not be generalizable to the entire category of tricyclic antidepressants.[0m
[31m        -----[0m
[31m        Final answer: There is no clear overall effect of the tricyclic antidepressant category of drugs on the risk of mortality after myocardial infarction, as the evidence is not uniform across the[0m
[31mcategory.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The revised reasoning is more accurate in reflecting the uncertainty across the tricyclic antidepressant category due to the lack of information for two of the drugs and evidence of [0m
[32mincreased risk for only one drug. The conclusion that there is no clear overall effect is appropriate given the available evidence. The reasoning now appropriately considers the overall evidence for [0m
[32mthe entire drug category and acknowledges that the evidence for an increased risk is specific to AMITRIPTYLINE HCL and may not apply to other drugs in the category."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The revised reasoning is more accurate in reflecting the uncertainty across the tricyclic antidepressant category due to the lack of information for two of the drugs and evidence of [0m
[34mincreased risk for only one drug. The conclusion that there is no clear overall effect is appropriate given the available evidence. The reasoning now appropriately considers the overall evidence for [0m
[34mthe entire drug category and acknowledges that the evidence for an increased risk is specific to AMITRIPTYLINE HCL and may not apply to other drugs in the category."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The revised reasoning is more accurate in reflecting the uncertainty across the tricyclic antidepressant category due to the lack of information for two of the drugs and evidence of [0m
[31mincreased risk for only one drug. The conclusion that there is no clear overall effect is appropriate given the available evidence. The reasoning now appropriately considers the overall evidence for [0m
[31mthe entire drug category and acknowledges that the evidence for an increased risk is specific to AMITRIPTYLINE HCL and may not apply to other drugs in the category.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.5[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.5[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"rare"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The available evidence does not provide a clear indication of the effect of tricyclic antidepressants as a category on mortality after myocardial infarction. While AMITRIPTYLINE [0m
[32mHCL may increase the risk, particularly if misused or in overdose, there is no information on the effects of DOXEPIN HCL and DESIPRAMINE. Therefore, the evidence is not uniform across the category, [0m
[32mand the increased risk associated with AMITRIPTYLINE HCL may not be generalizable to all tricyclic antidepressants."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-tricyclic antidepressant[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
